The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study
Introduction This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients. Methods A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive an...
Gespeichert in:
| Veröffentlicht in: | Asia-Pacific psychiatry 2016-09, Vol.8 (3), p.241-244 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 3 |
| container_start_page | 241 |
| container_title | Asia-Pacific psychiatry |
| container_volume | 8 |
| creator | Liang, Ying Cao, Changan Zhu, Cheng Wang, Chuanyue Zhang, Congpei Dong, Fang Yang, Fude Deng, Hong Yu, Jingjie Tang, Jisheng Su, Lei Xin, Limin Hong, Ling Gao, Minglong Tang, Muni Xie, Shiping Lu, Shuiping Liu, Tiebang Xu, Xiaojin Wang, Xijin Li, Xuanzi Wang, Xueyi Li, Yi Zhang, Yong Chen, Zhiyu Yu, Xin |
| description | Introduction
This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.
Methods
A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.
Results
A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.
Discussion
Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia. |
| doi_str_mv | 10.1111/appy.12238 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5071681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1806078643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4868-7772cc6ffbf2760e2f227b3ff8551cc809ddbf00a2d9c217409a4506593e7c723</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhyMEoqVw4QGQJS4IbYrt_LGXA9JqVVpQtfSwCDhZXmfcuHWcYCfdhvfgffGSdgUc8MWW_M2nmfklyXOCj0k8b2TXjceE0ow_SA4JK3hacEYf7t9lfpA8CeEK45KRPH-cHFCGKWYUHyY_1zUg0BpUb27AQQhIugoFqaEfUauRbEwYbOdNBcg4tKxNhAB1sjfg-oC2pq9RULX50Xa1B2fkW7RwiKdbgOsZ6nwbukk-Q20HLrVyA3aGmsH2RkUF-BkKxl1aSKVvUOiHanyaPNLSBnh2dx8ln9-frJdn6fmn0w_LxXmqcl7ylDFGlSq13mjKSgxUU8o2mda8KIhSHM-raqMxlrSaK0pYjucyL3BZzDNgitHsKHk3ebth00C1a8dLK-K0jfSjaKURf_84U4vL9kYUmJGSkyh4dSfw7fcBQi_iuhRYKx20QxCE4xKzmEAW0Zf_oFft4F0cb0cVeU5JhiP1eqJUXFzwoPfNECx2aYtd2uJ32hF-8Wf7e_Q-3giQCdgaC-N_VGJxcfHtXppONSb0cLuvkf5alCxjhfiyOhXr1cevK74-E6vsF91ExzU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1805442130</pqid></control><display><type>article</type><title>The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Liang, Ying ; Cao, Changan ; Zhu, Cheng ; Wang, Chuanyue ; Zhang, Congpei ; Dong, Fang ; Yang, Fude ; Deng, Hong ; Yu, Jingjie ; Tang, Jisheng ; Su, Lei ; Xin, Limin ; Hong, Ling ; Gao, Minglong ; Tang, Muni ; Xie, Shiping ; Lu, Shuiping ; Liu, Tiebang ; Xu, Xiaojin ; Wang, Xijin ; Li, Xuanzi ; Wang, Xueyi ; Li, Yi ; Zhang, Yong ; Chen, Zhiyu ; Yu, Xin</creator><creatorcontrib>Liang, Ying ; Cao, Changan ; Zhu, Cheng ; Wang, Chuanyue ; Zhang, Congpei ; Dong, Fang ; Yang, Fude ; Deng, Hong ; Yu, Jingjie ; Tang, Jisheng ; Su, Lei ; Xin, Limin ; Hong, Ling ; Gao, Minglong ; Tang, Muni ; Xie, Shiping ; Lu, Shuiping ; Liu, Tiebang ; Xu, Xiaojin ; Wang, Xijin ; Li, Xuanzi ; Wang, Xueyi ; Li, Yi ; Zhang, Yong ; Chen, Zhiyu ; Yu, Xin</creatorcontrib><description>Introduction
This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.
Methods
A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.
Results
A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.
Discussion
Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.</description><identifier>ISSN: 1758-5864</identifier><identifier>EISSN: 1758-5872</identifier><identifier>DOI: 10.1111/appy.12238</identifier><identifier>PMID: 27020720</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Amisulpride ; Antipsychotic Agents - therapeutic use ; antipsychotic agents/adverse effects ; Brief Report ; Brief Reports ; Chinese ; Female ; Humans ; Male ; Middle Aged ; Patients ; Prospective Studies ; Schizophrenia ; Schizophrenia - drug therapy ; Sulpiride - analogs & derivatives ; Sulpiride - therapeutic use ; Treatment Outcome ; Young Adult</subject><ispartof>Asia-Pacific psychiatry, 2016-09, Vol.8 (3), p.241-244</ispartof><rights>2016 The Authors Asia‐Pacific Psychiatry Published by John Wiley & Sons Australia, Ltd</rights><rights>2016 The Authors Asia-Pacific Psychiatry Published by John Wiley & Sons Australia, Ltd.</rights><rights>2016 John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4868-7772cc6ffbf2760e2f227b3ff8551cc809ddbf00a2d9c217409a4506593e7c723</citedby><cites>FETCH-LOGICAL-c4868-7772cc6ffbf2760e2f227b3ff8551cc809ddbf00a2d9c217409a4506593e7c723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fappy.12238$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fappy.12238$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27020720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liang, Ying</creatorcontrib><creatorcontrib>Cao, Changan</creatorcontrib><creatorcontrib>Zhu, Cheng</creatorcontrib><creatorcontrib>Wang, Chuanyue</creatorcontrib><creatorcontrib>Zhang, Congpei</creatorcontrib><creatorcontrib>Dong, Fang</creatorcontrib><creatorcontrib>Yang, Fude</creatorcontrib><creatorcontrib>Deng, Hong</creatorcontrib><creatorcontrib>Yu, Jingjie</creatorcontrib><creatorcontrib>Tang, Jisheng</creatorcontrib><creatorcontrib>Su, Lei</creatorcontrib><creatorcontrib>Xin, Limin</creatorcontrib><creatorcontrib>Hong, Ling</creatorcontrib><creatorcontrib>Gao, Minglong</creatorcontrib><creatorcontrib>Tang, Muni</creatorcontrib><creatorcontrib>Xie, Shiping</creatorcontrib><creatorcontrib>Lu, Shuiping</creatorcontrib><creatorcontrib>Liu, Tiebang</creatorcontrib><creatorcontrib>Xu, Xiaojin</creatorcontrib><creatorcontrib>Wang, Xijin</creatorcontrib><creatorcontrib>Li, Xuanzi</creatorcontrib><creatorcontrib>Wang, Xueyi</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zhang, Yong</creatorcontrib><creatorcontrib>Chen, Zhiyu</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><title>The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study</title><title>Asia-Pacific psychiatry</title><addtitle>Asia-Pacific Psychiatry</addtitle><description>Introduction
This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.
Methods
A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.
Results
A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.
Discussion
Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Amisulpride</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>antipsychotic agents/adverse effects</subject><subject>Brief Report</subject><subject>Brief Reports</subject><subject>Chinese</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Sulpiride - analogs & derivatives</subject><subject>Sulpiride - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1758-5864</issn><issn>1758-5872</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQhyMEoqVw4QGQJS4IbYrt_LGXA9JqVVpQtfSwCDhZXmfcuHWcYCfdhvfgffGSdgUc8MWW_M2nmfklyXOCj0k8b2TXjceE0ow_SA4JK3hacEYf7t9lfpA8CeEK45KRPH-cHFCGKWYUHyY_1zUg0BpUb27AQQhIugoFqaEfUauRbEwYbOdNBcg4tKxNhAB1sjfg-oC2pq9RULX50Xa1B2fkW7RwiKdbgOsZ6nwbukk-Q20HLrVyA3aGmsH2RkUF-BkKxl1aSKVvUOiHanyaPNLSBnh2dx8ln9-frJdn6fmn0w_LxXmqcl7ylDFGlSq13mjKSgxUU8o2mda8KIhSHM-raqMxlrSaK0pYjucyL3BZzDNgitHsKHk3ebth00C1a8dLK-K0jfSjaKURf_84U4vL9kYUmJGSkyh4dSfw7fcBQi_iuhRYKx20QxCE4xKzmEAW0Zf_oFft4F0cb0cVeU5JhiP1eqJUXFzwoPfNECx2aYtd2uJ32hF-8Wf7e_Q-3giQCdgaC-N_VGJxcfHtXppONSb0cLuvkf5alCxjhfiyOhXr1cevK74-E6vsF91ExzU</recordid><startdate>201609</startdate><enddate>201609</enddate><creator>Liang, Ying</creator><creator>Cao, Changan</creator><creator>Zhu, Cheng</creator><creator>Wang, Chuanyue</creator><creator>Zhang, Congpei</creator><creator>Dong, Fang</creator><creator>Yang, Fude</creator><creator>Deng, Hong</creator><creator>Yu, Jingjie</creator><creator>Tang, Jisheng</creator><creator>Su, Lei</creator><creator>Xin, Limin</creator><creator>Hong, Ling</creator><creator>Gao, Minglong</creator><creator>Tang, Muni</creator><creator>Xie, Shiping</creator><creator>Lu, Shuiping</creator><creator>Liu, Tiebang</creator><creator>Xu, Xiaojin</creator><creator>Wang, Xijin</creator><creator>Li, Xuanzi</creator><creator>Wang, Xueyi</creator><creator>Li, Yi</creator><creator>Zhang, Yong</creator><creator>Chen, Zhiyu</creator><creator>Yu, Xin</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>BSCLL</scope><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201609</creationdate><title>The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study</title><author>Liang, Ying ; Cao, Changan ; Zhu, Cheng ; Wang, Chuanyue ; Zhang, Congpei ; Dong, Fang ; Yang, Fude ; Deng, Hong ; Yu, Jingjie ; Tang, Jisheng ; Su, Lei ; Xin, Limin ; Hong, Ling ; Gao, Minglong ; Tang, Muni ; Xie, Shiping ; Lu, Shuiping ; Liu, Tiebang ; Xu, Xiaojin ; Wang, Xijin ; Li, Xuanzi ; Wang, Xueyi ; Li, Yi ; Zhang, Yong ; Chen, Zhiyu ; Yu, Xin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4868-7772cc6ffbf2760e2f227b3ff8551cc809ddbf00a2d9c217409a4506593e7c723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Amisulpride</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>antipsychotic agents/adverse effects</topic><topic>Brief Report</topic><topic>Brief Reports</topic><topic>Chinese</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Sulpiride - analogs & derivatives</topic><topic>Sulpiride - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Ying</creatorcontrib><creatorcontrib>Cao, Changan</creatorcontrib><creatorcontrib>Zhu, Cheng</creatorcontrib><creatorcontrib>Wang, Chuanyue</creatorcontrib><creatorcontrib>Zhang, Congpei</creatorcontrib><creatorcontrib>Dong, Fang</creatorcontrib><creatorcontrib>Yang, Fude</creatorcontrib><creatorcontrib>Deng, Hong</creatorcontrib><creatorcontrib>Yu, Jingjie</creatorcontrib><creatorcontrib>Tang, Jisheng</creatorcontrib><creatorcontrib>Su, Lei</creatorcontrib><creatorcontrib>Xin, Limin</creatorcontrib><creatorcontrib>Hong, Ling</creatorcontrib><creatorcontrib>Gao, Minglong</creatorcontrib><creatorcontrib>Tang, Muni</creatorcontrib><creatorcontrib>Xie, Shiping</creatorcontrib><creatorcontrib>Lu, Shuiping</creatorcontrib><creatorcontrib>Liu, Tiebang</creatorcontrib><creatorcontrib>Xu, Xiaojin</creatorcontrib><creatorcontrib>Wang, Xijin</creatorcontrib><creatorcontrib>Li, Xuanzi</creatorcontrib><creatorcontrib>Wang, Xueyi</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zhang, Yong</creatorcontrib><creatorcontrib>Chen, Zhiyu</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><collection>Istex</collection><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asia-Pacific psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Ying</au><au>Cao, Changan</au><au>Zhu, Cheng</au><au>Wang, Chuanyue</au><au>Zhang, Congpei</au><au>Dong, Fang</au><au>Yang, Fude</au><au>Deng, Hong</au><au>Yu, Jingjie</au><au>Tang, Jisheng</au><au>Su, Lei</au><au>Xin, Limin</au><au>Hong, Ling</au><au>Gao, Minglong</au><au>Tang, Muni</au><au>Xie, Shiping</au><au>Lu, Shuiping</au><au>Liu, Tiebang</au><au>Xu, Xiaojin</au><au>Wang, Xijin</au><au>Li, Xuanzi</au><au>Wang, Xueyi</au><au>Li, Yi</au><au>Zhang, Yong</au><au>Chen, Zhiyu</au><au>Yu, Xin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study</atitle><jtitle>Asia-Pacific psychiatry</jtitle><addtitle>Asia-Pacific Psychiatry</addtitle><date>2016-09</date><risdate>2016</risdate><volume>8</volume><issue>3</issue><spage>241</spage><epage>244</epage><pages>241-244</pages><issn>1758-5864</issn><eissn>1758-5872</eissn><abstract>Introduction
This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.
Methods
A multicenter, single‐arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.
Results
A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.
Discussion
Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>27020720</pmid><doi>10.1111/appy.12238</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-5864 |
| ispartof | Asia-Pacific psychiatry, 2016-09, Vol.8 (3), p.241-244 |
| issn | 1758-5864 1758-5872 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5071681 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Adolescent Adult Amisulpride Antipsychotic Agents - therapeutic use antipsychotic agents/adverse effects Brief Report Brief Reports Chinese Female Humans Male Middle Aged Patients Prospective Studies Schizophrenia Schizophrenia - drug therapy Sulpiride - analogs & derivatives Sulpiride - therapeutic use Treatment Outcome Young Adult |
| title | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T10%3A14%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effectiveness%20and%20safety%20of%20amisulpride%20in%20Chinese%20patients%20with%20schizophrenia:%20An%208-week,%20prospective,%20open-label,%20multicenter,%20single-arm%20study&rft.jtitle=Asia-Pacific%20psychiatry&rft.au=Liang,%20Ying&rft.date=2016-09&rft.volume=8&rft.issue=3&rft.spage=241&rft.epage=244&rft.pages=241-244&rft.issn=1758-5864&rft.eissn=1758-5872&rft_id=info:doi/10.1111/appy.12238&rft_dat=%3Cproquest_pubme%3E1806078643%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1805442130&rft_id=info:pmid/27020720&rfr_iscdi=true |